Argentina Ministry of Health Clinical Trial: Ivermectin Shows Benefit Treating Outpatients with Mild COVID-19

A recent study sponsored by the Ministry of Health of Argentina sought to evaluate the use of ivermectin in mild stage outpatients to heal and /or reverse the progression of COVID-19 disease towards the development of moderate or severe stages. The premise behind this government-sponsored study was that the emergence of COVID-19 requires alternative treatments based on the reuse of drugs as a strategy to prevent the progression of the disease in patients infected with SARS-CoV-2. The sponsor designed a cluster assigned clinical trial (2:1) in outpatients with a total of 234. The subjects were divided into experimental (110) and control groups (62), with the experimental group receiving orally 4 drops of 6mg (24) mg every 7 days for 4 weeks. The study team concluded that a significant reduction in the symptom numbers was observed in the experimental group when medical examination was conducted from 5th to 9th days, after commencing treatment (p=0.0026). Past the 10th and 14th days, the investigators observed a progressive reduction of the percentage of symptom numbers, however they were not significant in both groups. The study sponsors concl...